Novartis Pharmaceuticals (NVS.US) first radioligand therapy drug Lutathera receives dual indications simultaneously.

Zhitong Finance APP learned that Novartis(NVS.US) announced that its radioligand therapy (RLT) drug Lutathera (Lutetium [177Lu] Lu-PSMA-617) has simultaneously received approval from the National Medical Products Administration for two indications: the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult patients with positive prostate-specific membrane antigen (PSMA) who have previously received androgen receptor pathway inhibitors (ARPI) and are suitable for delaying chemotherapy, and in adult patients with PSMA-positive mCRPC who have disease progression after previous ARPI and taxane chemotherapy.